Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nintedanib - Boehringer Ingelheim

Drug Profile

Nintedanib - Boehringer Ingelheim

Alternative Names: BIBF-1120; Intedanib; OFEV; Ofev; Vargatef

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Atrium Health; Boehringer Ingelheim; Duke University; European Organisation for Research and Treatment of Cancer; Lurie Cancer Center; M. D. Anderson Cancer Center; National Cancer Institute (USA); Northwestern University; Roswell Park Cancer Institute; University College London; University of Alabama at Birmingham; University of Texas Southwestern Medical Center
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Systemic scleroderma; Idiopathic pulmonary fibrosis; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Interstitial lung diseases; Non-small cell lung cancer; Systemic scleroderma
  • Phase III Colorectal cancer; Mesothelioma; Ovarian cancer
  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Inflammatory breast cancer; Liver cancer; Peritoneal cancer; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Salivary gland cancer
  • No development reported Multiple myeloma; Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 10 Oct 2019 Nintedanib receives breakthrough therapy designation for Interstitial lung diseases in USA
  • 30 Sep 2019 Efficacy and adverse events data from the phase III INBUILD® trial in Interstitial lung disease released by Boehringer Ingelheim
  • 23 Sep 2019 Boehringer Ingelheim plans a phase III trial for Interstitial lung disease (In Children, In adolescents) in October 2019 (NCT04093024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top